This Benign Prostatic Hyperplasia - Pipeline Insight, 2021 provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age. The symptoms of benign prostatic hyperplasia include sensation of incomplete bladder emptying, straining to void, urinary hesitancy, weak urinary stream, dysuria, nocturia, urinary frequency, and urinary urgency. Assessment of medical history of the patient and physical examination, including a digital rectal examination (DRE) and urinalysis are done for diagnosis of BPH. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH. The two major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors.
Benign Prostatic Hyperplasia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Benign Prostatic Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign Prostatic Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign Prostatic Hyperplasia.
This segment of the Benign Prostatic Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fexapotide: Nymox Pharmaceutical
Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In May 2021, Nymox Pharmaceutical announced that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before September 15, 2021.
AIV007: AiViva BioPharma
AIV007 is a novel formulation using company's JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFß1 mRNA expression and TGFß1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for benign prostatic hyperplasia (BPH), and certain solid tumors.
There are approx. 12+ key companies which are developing the therapies for Benign Prostatic Hyperplasia. The companies which have their Benign Prostatic Hyperplasia drug candidates in the most advanced stage, i.e. Preregistration include, Nymox Pharmaceutical.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Benign Prostatic Hyperplasia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign Prostatic Hyperplasia drugs.
Geography Covered
- Global coverage
Benign Prostatic Hyperplasia Understanding
Benign Prostatic Hyperplasia: Overview
Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age. The symptoms of benign prostatic hyperplasia include sensation of incomplete bladder emptying, straining to void, urinary hesitancy, weak urinary stream, dysuria, nocturia, urinary frequency, and urinary urgency. Assessment of medical history of the patient and physical examination, including a digital rectal examination (DRE) and urinalysis are done for diagnosis of BPH. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH. The two major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors.
Benign Prostatic Hyperplasia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Benign Prostatic Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign Prostatic Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign Prostatic Hyperplasia.
Benign Prostatic Hyperplasia Emerging Drugs Chapters
This segment of the Benign Prostatic Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Benign Prostatic Hyperplasia Emerging Drugs
Fexapotide: Nymox Pharmaceutical
Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In May 2021, Nymox Pharmaceutical announced that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before September 15, 2021.
AIV007: AiViva BioPharma
AIV007 is a novel formulation using company's JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFß1 mRNA expression and TGFß1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for benign prostatic hyperplasia (BPH), and certain solid tumors.
Benign Prostatic Hyperplasia: Therapeutic Assessment
This segment of the report provides insights about the different Benign Prostatic Hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Benign Prostatic Hyperplasia
There are approx. 12+ key companies which are developing the therapies for Benign Prostatic Hyperplasia. The companies which have their Benign Prostatic Hyperplasia drug candidates in the most advanced stage, i.e. Preregistration include, Nymox Pharmaceutical.
Phases
This report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Benign Prostatic Hyperplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Benign Prostatic Hyperplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign Prostatic Hyperplasia drugs.
Benign Prostatic Hyperplasia Report Insights
- Benign Prostatic Hyperplasia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Benign Prostatic Hyperplasia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Benign Prostatic Hyperplasia drugs?
- How many Benign Prostatic Hyperplasia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign Prostatic Hyperplasia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign Prostatic Hyperplasia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Benign Prostatic Hyperplasia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Nymox Pharmaceutical
- ASKA Pharmaceutical
- Otsuka Pharmaceutical
- Aiviva BioPharma
- Veru Helathcare
- Boryung Pharmaceutical
- KAEL-GemVax
- Dong-A ST/Mezzion
Key Products
- Fexapotide
- AKP009
- Tolvaptan
- AIV007
- Tamsulosin delayed-release
- BR9006
- Tertomotide
- Udenafil
Table of Contents
IntroductionExecutive Summary
Benign Prostatic Hyperplasia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Benign Prostatic Hyperplasia - Analytical Perspective
Late Stage Products (Preregistration)
- Comparative Analysis
Fexapotide: Nymox Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Tolvaptan: Otsuka Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Lenvatinib: AiViva BioPharma
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Benign Prostatic Hyperplasia Key Companies
Benign Prostatic Hyperplasia Key Products
Benign Prostatic Hyperplasia- Unmet Needs
Benign Prostatic Hyperplasia- Market Drivers and Barriers
Benign Prostatic Hyperplasia- Future Perspectives and Conclusion
Benign Prostatic Hyperplasia Analyst Views
AppendixList of Tables
Table 1 Total Products for Benign Prostatic Hyperplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Benign Prostatic Hyperplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Nymox Pharmaceutical
- ASKA Pharmaceutical
- Otsuka Pharmaceutical
- Aiviva BioPharma
- Veru Helathcare
- Boryung Pharmaceutical
- KAEL-GemVax
- Dong-A ST/Mezzion
